<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Medora | Medical Scores</title>
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<script type="module" src="auth-guard.js"></script>

<style>
body{
  margin:0;
  font-family:Segoe UI,Arial;
  background:radial-gradient(circle at top,#1c2541,#020617);
  color:#eaeaea;
}

/* HEADER */
header{
  padding:22px 40px;
  background:rgba(28,37,65,.95);
  display:flex;
  justify-content:space-between;
  align-items:center;
}
header h2{margin:0}
.back-btn{
  background:#3a86ff;
  color:#fff;
  padding:10px 16px;
  border-radius:10px;
  text-decoration:none;
  font-size:14px;
}

/* CONTENT */
.wrapper{
  max-width:1000px;
  margin:auto;
  padding:40px;
}

input{
  width:100%;
  padding:16px;
  border-radius:14px;
  border:none;
  background:#020617;
  color:#fff;
  font-size:16px;
}

/* AUTOCOMPLETE */
#suggestions{
  background:#020617;
  border-radius:14px;
  margin-top:10px;
  overflow:hidden;
  border:1px solid rgba(255,255,255,.08);
}
.suggestion{
  padding:14px 18px;
  cursor:pointer;
  border-bottom:1px solid rgba(255,255,255,.05);
}
.suggestion:last-child{border-bottom:none}
.suggestion:hover{background:#24355c}

/* SCORE CARD */
.score{
  background:linear-gradient(180deg,#1c2541,#16203a);
  padding:18px 22px;
  border-radius:16px;
  margin-bottom:14px;
  cursor:pointer;
  border:1px solid rgba(255,255,255,.05);
}
.score:hover{background:#24355c}
.score h3{margin:0}
.score span{font-size:13px;color:#b0bcd6}

/* MODAL */
.modal{
  position:fixed;
  inset:0;
  display:none;
  background:rgba(0,0,0,.75);
  align-items:center;
  justify-content:center;
  z-index:999;
}
.modal-box{
  background:#0f172a;
  max-width:900px;
  width:90%;
  max-height:85vh;
  overflow-y:auto;
  padding:30px;
  border-radius:18px;
}
.modal-box h2{margin-top:0}
.modal-box h4{color:#93c5fd}
.modal-box p,li{line-height:1.7}
.close{
  margin-top:20px;
  padding:10px 18px;
  border:none;
  border-radius:10px;
  background:#3a86ff;
  color:#fff;
  cursor:pointer;
}
</style>
</head>

<body>

<header>
  <h2>üß† Medical Scores Library</h2>
  <a href="dashboard.html" class="back-btn">‚¨Ö Dashboard</a>
</header>

<div class="wrapper">
  <input id="search" placeholder="Search medical score...">
  <div id="suggestions" style="display:none"></div>
  <div id="list"></div>
</div>

<div class="modal" id="modal" onclick="closeModal()">
  <div class="modal-box" onclick="event.stopPropagation()">
    <div id="content"></div>
    <button class="close" onclick="closeModal()">Close</button>
  </div>
</div>

<script>
/* =====================
   SCORES DATA (1‚Äì10)
===================== */
const scores = [
{
name:"APGAR Score",
keywords:["apgar","newborn","neonatal"],
html:`
<h4>Definition</h4>
<p>The APGAR score is a rapid clinical assessment tool used to evaluate the physiological adaptation of a newborn immediately after birth.</p>

<h4>Historical Background</h4>
<p>Developed in 1952 by Dr. Virginia Apgar, an anesthesiologist.</p>

<h4>Components (0‚Äì2 each)</h4>
<ul>
<li><b>Appearance:</b> Blue/pale ‚Üí pink</li>
<li><b>Pulse:</b> Absent ‚Üí ‚â•100 bpm</li>
<li><b>Grimace:</b> No response ‚Üí Cry</li>
<li><b>Activity:</b> Limp ‚Üí Active motion</li>
<li><b>Respiration:</b> Absent ‚Üí Good cry</li>
</ul>

<h4>Scoring</h4>
<p>Total: 0‚Äì10 at 1 and 5 minutes.</p>

<h4>Interpretation</h4>
<ul>
<li>7‚Äì10: Normal</li>
<li>4‚Äì6: Moderate depression</li>
<li>0‚Äì3: Severe distress</li>
</ul>

<h4>Clinical Use</h4>
<ul>
<li>Immediate neonatal resuscitation</li>
<li>Outcome comparison</li>
</ul>

<h4>Limitations</h4>
<ul>
<li>Not predictive of long-term outcomes</li>
<li>Affected by prematurity & drugs</li>
</ul>

<h4>Exam Pearl</h4>
<p>5-minute APGAR is more prognostic.</p>
`
},

{
name:"Glasgow Coma Scale (GCS)",
keywords:["gcs","coma","neurology","trauma"],
html:`
<h4>Definition</h4>
<p>Standardized assessment of consciousness.</p>

<h4>Components</h4>
<ul>
<li><b>Eye (E):</b> 4‚Äì1</li>
<li><b>Verbal (V):</b> 5‚Äì1</li>
<li><b>Motor (M):</b> 6‚Äì1</li>
</ul>

<h4>Total Score</h4>
<p>3‚Äì15</p>

<h4>Severity</h4>
<ul>
<li>13‚Äì15: Mild</li>
<li>9‚Äì12: Moderate</li>
<li>‚â§8: Severe (coma)</li>
</ul>

<h4>Clinical Use</h4>
<ul>
<li>Trauma</li>
<li>ICU monitoring</li>
<li>Coma prognosis</li>
</ul>

<h4>Limitations</h4>
<ul>
<li>Intubation affects verbal score</li>
<li>Sedatives confound results</li>
</ul>

<h4>Exam Pearl</h4>
<p>GCS ‚â§8 ‚Üí Intubate.</p>
`
},

{
name:"Bishop Score",
keywords:["bishop","labor","induction"],
html:`
<h4>Definition</h4>
<p>Predicts success of labor induction.</p>

<h4>Components</h4>
<ul>
<li>Dilation</li>
<li>Effacement</li>
<li>Station</li>
<li>Consistency</li>
<li>Position</li>
</ul>

<h4>Total Score</h4>
<p>0‚Äì13</p>

<h4>Interpretation</h4>
<ul>
<li>‚â§5: Unfavorable</li>
<li>‚â•8: Favorable</li>
</ul>

<h4>Clinical Use</h4>
<p>Guides induction strategy.</p>

<h4>Limitations</h4>
<p>Subjective examiner variability.</p>

<h4>Exam Pearl</h4>
<p>Low score ‚Üí cervical ripening.</p>
`
},

{
name:"Wells Score ‚Äì Deep Vein Thrombosis",
keywords:["wells dvt","dvt","thrombosis"],
html:`
<h4>Purpose</h4>
<p>Estimates pre-test probability of DVT.</p>

<h4>Interpretation</h4>
<ul>
<li>‚â§0: Low</li>
<li>1‚Äì2: Moderate</li>
<li>‚â•3: High</li>
</ul>

<h4>Clinical Algorithm</h4>
<ul>
<li>Low ‚Üí D-dimer</li>
<li>High ‚Üí Ultrasound</li>
</ul>

<h4>Limitation</h4>
<p>Not diagnostic alone.</p>
`
},

{
name:"Wells Score ‚Äì Pulmonary Embolism",
keywords:["wells pe","pulmonary embolism"],
html:`
<h4>Purpose</h4>
<p>Estimates probability of pulmonary embolism.</p>

<h4>Interpretation</h4>
<ul>
<li>‚â§4: PE unlikely</li>
<li>>4: PE likely</li>
</ul>

<h4>Clinical Use</h4>
<p>Guides need for CT pulmonary angiography.</p>
`
},

{
name:"CHA‚ÇÇDS‚ÇÇ-VASc Score",
keywords:["cha2ds2vasc","af","stroke"],
html:`
<h4>Purpose</h4>
<p>Estimates stroke risk in atrial fibrillation.</p>

<h4>Interpretation</h4>
<ul>
<li>0: No anticoagulation</li>
<li>1: Consider</li>
<li>‚â•2: Anticoagulation indicated</li>
</ul>

<h4>Exam Pearl</h4>
<p>More sensitive than CHADS‚ÇÇ.</p>
`
},

{
name:"HAS-BLED Score",
keywords:["has-bled","bleeding","af"],
html:`
<h4>Purpose</h4>
<p>Assesses bleeding risk in AF patients.</p>

<h4>Interpretation</h4>
<p>Score ‚â•3 ‚Üí high bleeding risk (not contraindication).</p>
`
},

{
name:"CURB-65 Score",
keywords:["curb-65","pneumonia"],
html:`
<h4>Purpose</h4>
<p>Pneumonia severity assessment.</p>

<h4>Management</h4>
<ul>
<li>0‚Äì1: Outpatient</li>
<li>2: Admit</li>
<li>‚â•3: ICU</li>
</ul>
`
},

{
name:"SOFA Score",
keywords:["sofa","sepsis","organ failure"],
html:`
<h4>Purpose</h4>
<p>Quantifies organ failure severity.</p>

<h4>Key Concept</h4>
<p>Increase ‚â•2 points = organ dysfunction.</p>
`
},

{
name:"qSOFA",
keywords:["qsofa","sepsis","icu"],
html:`
<h4>Criteria</h4>
<ul>
<li>RR ‚â•22</li>
<li>SBP ‚â§100</li>
<li>Altered mental status</li>
</ul>

<h4>Interpretation</h4>
<p>‚â•2 ‚Üí high mortality risk.</p>
`
},

{
name:"APACHE II Score",
keywords:["apache","apache ii","icu","mortality","critical care","severity"],
html:`
<h4>Definition</h4>
<p>A severity-of-disease classification system used to estimate hospital mortality in ICU patients.</p>

<h4>Components</h4>
<ul>
<li>Acute Physiology Score (12 variables)</li>
<li>Age points</li>
<li>Chronic health points</li>
</ul>

<h4>Total Score</h4>
<p>0‚Äì71 (higher score = higher mortality)</p>

<h4>Clinical Use</h4>
<p>Prognosis, ICU outcome comparison, research stratification.</p>

<h4>Limitations</h4>
<ul>
<li>Calculated only in first 24 hours</li>
<li>Not for individual treatment decisions</li>
</ul>

<h4>Exam Pearl</h4>
<p>APACHE II is prognostic, not diagnostic.</p>
`
},

{
name:"NIH Stroke Scale (NIHSS)",
keywords:["nihss","nih stroke scale","stroke","neurology","tpa"],
html:`
<h4>Definition</h4>
<p>A standardized neurological examination to quantify stroke severity.</p>

<h4>Score Range</h4>
<p>0‚Äì42</p>

<h4>Severity</h4>
<ul>
<li>0: No stroke</li>
<li>1‚Äì4: Minor</li>
<li>5‚Äì15: Moderate</li>
<li>16‚Äì20: Moderate‚Äìsevere</li>
<li>>20: Severe</li>
</ul>

<h4>Clinical Use</h4>
<p>Thrombolysis eligibility, stroke unit monitoring, prognosis.</p>

<h4>Limitations</h4>
<p>Underestimates posterior circulation strokes.</p>

<h4>Exam Pearl</h4>
<p>NIHSS >25 increases hemorrhagic transformation risk after tPA.</p>
`
},

{
name:"TIMI Risk Score (ACS)",
keywords:["timi","timi score","acs","nstemi","unstable angina"],
html:`
<h4>Definition</h4>
<p>Risk stratification tool for unstable angina and NSTEMI.</p>

<h4>Score Range</h4>
<p>0‚Äì7</p>

<h4>Clinical Use</h4>
<p>Predicts risk of death, myocardial infarction, and urgent revascularization.</p>

<h4>Limitations</h4>
<ul>
<li>Binary variables</li>
<li>Less accurate than GRACE score</li>
</ul>
`
},

{
name:"GRACE Score",
keywords:["grace","grace score","acs","cardiology","mortality"],
html:`
<h4>Definition</h4>
<p>Predicts in-hospital and 6-month mortality in acute coronary syndromes.</p>

<h4>Variables</h4>
<ul>
<li>Age</li>
<li>Heart rate</li>
<li>Systolic blood pressure</li>
<li>Serum creatinine</li>
<li>Killip class</li>
<li>Cardiac arrest</li>
<li>ST deviation</li>
<li>Elevated troponin</li>
</ul>

<h4>Clinical Use</h4>
<p>ESC guideline‚Äìrecommended for ACS risk stratification.</p>

<h4>Exam Pearl</h4>
<p>GRACE score >140 ‚Üí early invasive strategy.</p>
`
},

{
name:"Child‚ÄìPugh Score",
keywords:["child pugh","cirrhosis","liver","hepatology"],
html:`
<h4>Definition</h4>
<p>Assesses severity and prognosis of chronic liver disease, mainly cirrhosis.</p>

<h4>Classes</h4>
<ul>
<li>Class A (5‚Äì6): Well compensated</li>
<li>Class B (7‚Äì9): Significant disease</li>
<li>Class C (10‚Äì15): Decompensated</li>
</ul>

<h4>Clinical Use</h4>
<p>Surgical risk assessment and prognosis.</p>

<h4>Limitations</h4>
<p>Includes subjective variables; less precise than MELD.</p>
`
},

{
name:"MELD Score",
keywords:["meld","liver transplant","cirrhosis","hepatology"],
html:`
<h4>Definition</h4>
<p>Model for End-Stage Liver Disease predicting 3-month mortality.</p>

<h4>Variables</h4>
<ul>
<li>Serum bilirubin</li>
<li>INR</li>
<li>Serum creatinine</li>
</ul>

<h4>Clinical Use</h4>
<p>Liver transplant allocation and prognosis.</p>

<h4>Limitations</h4>
<p>Underestimates cholestatic liver disease.</p>

<h4>Exam Pearl</h4>
<p>MELD is for allocation, Child‚ÄìPugh is for classification.</p>
`
},

{
name:"Alvarado Score",
keywords:["alvarado","appendicitis","surgery","abdomen"],
html:`
<h4>Definition</h4>
<p>Clinical score estimating probability of acute appendicitis.</p>

<h4>Score Range</h4>
<p>0‚Äì10</p>

<h4>Interpretation</h4>
<ul>
<li>‚â§4: Appendicitis unlikely</li>
<li>5‚Äì6: Observe</li>
<li>‚â•7: Surgical consultation</li>
</ul>

<h4>Limitations</h4>
<p>Less accurate in women, children, and elderly.</p>
`
},

{
name:"Ranson Criteria",
keywords:["ranson","pancreatitis","acute pancreatitis","gi"],
html:`
<h4>Definition</h4>
<p>Predicts severity and mortality in acute pancreatitis.</p>

<h4>Key Concept</h4>
<p>Criteria assessed at admission and at 48 hours.</p>

<h4>Interpretation</h4>
<p>‚â•3 criteria indicate severe pancreatitis.</p>

<h4>Limitations</h4>
<p>Requires 48 hours; less used today.</p>
`
},

{
name:"BISAP Score",
keywords:["bisap","pancreatitis","icu","gi"],
html:`
<h4>Definition</h4>
<p>Early predictor of mortality in acute pancreatitis.</p>

<h4>Components</h4>
<ul>
<li>BUN >25</li>
<li>Impaired mental status</li>
<li>SIRS</li>
<li>Age >60</li>
<li>Pleural effusion</li>
</ul>

<h4>Advantage</h4>
<p>Simple and early risk stratification.</p>
`
},

{
name:"Glasgow-Blatchford Score",
keywords:["blatchford","gbs","gi bleeding","upper gi"],
html:`
<h4>Definition</h4>
<p>Predicts need for intervention in upper gastrointestinal bleeding.</p>

<h4>Clinical Use</h4>
<p>Score 0 allows safe outpatient management.</p>

<h4>Advantage</h4>
<p>No endoscopy required initially.</p>
`
}

,
{
name:"Rockall Score (Upper GI Bleeding)",
keywords:["rockall","upper gi bleeding","ugi bleeding","rebleeding","endoscopy"],
html:`
<h4>Definition</h4>
<p>A risk stratification tool used to predict mortality and rebleeding in patients with upper gastrointestinal bleeding.</p>

<h4>Structure</h4>
<ul>
<li>Pre-endoscopy Rockall</li>
<li>Complete Rockall (post-endoscopy)</li>
</ul>

<h4>Components</h4>
<ul>
<li>Age (0‚Äì2)</li>
<li>Shock ‚Äì BP & HR (0‚Äì2)</li>
<li>Comorbidity (0‚Äì3)</li>
<li>Diagnosis ‚Äì endoscopic (0‚Äì2)</li>
<li>Stigmata of bleeding (0‚Äì2)</li>
</ul>

<h4>Total Score</h4>
<p>0‚Äì11</p>

<h4>Interpretation</h4>
<ul>
<li>‚â§2: Low risk</li>
<li>‚â•8: High mortality risk</li>
</ul>

<h4>Clinical Use</h4>
<p>Prognosis after UGIB and identification of patients needing intensive monitoring.</p>

<h4>Limitations</h4>
<ul>
<li>Requires endoscopy for full accuracy</li>
<li>Less sensitive than Glasgow-Blatchford for initial triage</li>
</ul>

<h4>Exam Pearl</h4>
<p>GBS predicts need for intervention, Rockall predicts mortality.</p>
`
},

{
name:"Framingham Risk Score",
keywords:["framingham","cv risk","cardiovascular risk","cholesterol","primary prevention"],
html:`
<h4>Definition</h4>
<p>Estimates 10-year risk of developing cardiovascular disease.</p>

<h4>Population</h4>
<p>Derived from the Framingham Heart Study (USA).</p>

<h4>Variables</h4>
<ul>
<li>Age</li>
<li>Sex</li>
<li>Total cholesterol</li>
<li>HDL cholesterol</li>
<li>Blood pressure</li>
<li>Smoking</li>
<li>Diabetes</li>
</ul>

<h4>Output</h4>
<p>Percentage risk (e.g. 10%, 20%).</p>

<h4>Risk Categories</h4>
<ul>
<li>&lt;10%: Low</li>
<li>10‚Äì20%: Intermediate</li>
<li>&gt;20%: High</li>
</ul>

<h4>Limitations</h4>
<p>Overestimates risk in non-Western populations and largely replaced by ASCVD.</p>
`
},

{
name:"ASCVD Risk Calculator",
keywords:["ascvd","atherosclerotic","statin","cardiovascular prevention"],
html:`
<h4>Definition</h4>
<p>Predicts 10-year and lifetime risk of atherosclerotic cardiovascular disease.</p>

<h4>Outcomes Predicted</h4>
<ul>
<li>Myocardial infarction</li>
<li>Stroke</li>
<li>Cardiovascular death</li>
</ul>

<h4>Variables</h4>
<ul>
<li>Age</li>
<li>Sex</li>
<li>Race</li>
<li>Total & HDL cholesterol</li>
<li>Systolic BP</li>
<li>Diabetes</li>
<li>Smoking</li>
<li>Antihypertensive therapy</li>
</ul>

<h4>Interpretation</h4>
<p>‚â•7.5% ‚Üí consider statin therapy.</p>

<h4>Limitations</h4>
<p>Less accurate &lt;40 years and not validated &gt;79 years.</p>
`
},

{
name:"ABCD¬≤ Score (TIA)",
keywords:["abcd2","tia","stroke risk","neurology"],
html:`
<h4>Definition</h4>
<p>Predicts early stroke risk after transient ischemic attack.</p>

<h4>Components</h4>
<ul>
<li>Age ‚â•60</li>
<li>Blood pressure ‚â•140/90</li>
<li>Clinical features (1‚Äì2 points)</li>
<li>Duration (1‚Äì2 points)</li>
<li>Diabetes</li>
</ul>

<h4>Score Range</h4>
<p>0‚Äì7</p>

<h4>Interpretation</h4>
<ul>
<li>0‚Äì3: Low risk</li>
<li>4‚Äì5: Moderate risk</li>
<li>6‚Äì7: High risk ‚Üí hospital admission</li>
</ul>

<h4>Limitations</h4>
<p>Does not include imaging and underestimates posterior circulation TIA.</p>
`
},

{
name:"Barthel Index",
keywords:["barthel","adl","functional status","rehabilitation"],
html:`
<h4>Definition</h4>
<p>Measures functional independence in activities of daily living.</p>

<h4>Activities Assessed</h4>
<ul>
<li>Feeding</li>
<li>Bathing</li>
<li>Grooming</li>
<li>Dressing</li>
<li>Bowel & bladder control</li>
<li>Toilet use</li>
<li>Transfers</li>
<li>Mobility</li>
<li>Stairs</li>
</ul>

<h4>Score Range</h4>
<p>0‚Äì100</p>

<h4>Interpretation</h4>
<ul>
<li>0‚Äì20: Total dependence</li>
<li>21‚Äì60: Severe</li>
<li>61‚Äì90: Moderate</li>
<li>91‚Äì100: Minimal dependence</li>
</ul>

<h4>Clinical Use</h4>
<p>Rehabilitation, stroke recovery, geriatrics.</p>
`
},

{
name:"Karnofsky Performance Status (KPS)",
keywords:["karnofsky","performance status","oncology"],
html:`
<h4>Definition</h4>
<p>Quantifies functional impairment in cancer patients.</p>

<h4>Scale</h4>
<ul>
<li>100: Normal</li>
<li>70: Cares for self</li>
<li>50: Requires assistance</li>
<li>0: Death</li>
</ul>

<h4>Clinical Use</h4>
<p>Chemotherapy tolerance, prognosis, clinical trials eligibility.</p>

<h4>Limitations</h4>
<p>Subjective with inter-observer variability.</p>
`
},

{
name:"ECOG Performance Status",
keywords:["ecog","performance status","oncology","chemotherapy"],
html:`
<h4>Definition</h4>
<p>Simplified functional assessment used in oncology.</p>

<h4>Scale</h4>
<ul>
<li>0: Fully active</li>
<li>1: Restricted strenuous activity</li>
<li>2: Ambulatory, unable to work</li>
<li>3: Limited self-care</li>
<li>4: Completely disabled</li>
<li>5: Dead</li>
</ul>

<h4>Exam Pearl</h4>
<p>ECOG ‚â•3 indicates poor chemotherapy tolerance.</p>
`
},

{
name:"ASA Physical Status Classification",
keywords:["asa","anesthesia","preoperative risk"],
html:`
<h4>Definition</h4>
<p>Preoperative assessment of anesthetic risk.</p>

<h4>Classes</h4>
<ul>
<li>I: Healthy</li>
<li>II: Mild systemic disease</li>
<li>III: Severe systemic disease</li>
<li>IV: Severe disease, constant threat to life</li>
<li>V: Moribund</li>
<li>VI: Brain-dead (organ donor)</li>
</ul>

<h4>Limitations</h4>
<p>Subjective and does not include operative risk.</p>
`
},

{
name:"CHADS‚ÇÇ Score",
keywords:["chads2","atrial fibrillation","stroke risk"],
html:`
<h4>Definition</h4>
<p>Older scoring system for stroke risk in atrial fibrillation.</p>

<h4>Components</h4>
<ul>
<li>CHF</li>
<li>Hypertension</li>
<li>Age ‚â•75</li>
<li>Diabetes</li>
<li>Stroke/TIA (2 points)</li>
</ul>

<h4>Score Range</h4>
<p>0‚Äì6</p>

<h4>Status</h4>
<p>Largely replaced by CHA‚ÇÇDS‚ÇÇ-VASc.</p>

<h4>Exam Pearl</h4>
<p>Underestimates stroke risk in low-risk patients.</p>
`
},

{
name:"PESI Score",
keywords:["pesi","pulmonary embolism","pe severity","mortality"],
html:`
<h4>Definition</h4>
<p>Predicts 30-day mortality in pulmonary embolism.</p>

<h4>Variables</h4>
<ul>
<li>Age</li>
<li>Male sex</li>
<li>Cancer</li>
<li>Heart failure</li>
<li>Chronic lung disease</li>
<li>HR ‚â•110</li>
<li>SBP &lt;100</li>
<li>RR ‚â•30</li>
<li>Temperature &lt;36¬∞C</li>
<li>Altered mental status</li>
<li>O‚ÇÇ saturation &lt;90%</li>
</ul>

<h4>Risk Classes</h4>
<ul>
<li>I‚ÄìII: Low risk (outpatient possible)</li>
<li>III‚ÄìV: High risk (hospitalization)</li>
</ul>

<h4>Clinical Use</h4>
<p>Decides outpatient vs inpatient treatment.</p>
`
},

{
name:"NEWS2 Score",
keywords:["news2","early warning score","sepsis","deterioration"],
html:`
<h4>Definition</h4>
<p>Physiological scoring system to identify early clinical deterioration.</p>

<h4>Developed By</h4>
<p>Royal College of Physicians (UK).</p>

<h4>Physiological Parameters</h4>
<ul>
<li>Respiratory rate</li>
<li>Oxygen saturation</li>
<li>Supplemental oxygen</li>
<li>Temperature</li>
<li>Systolic blood pressure</li>
<li>Heart rate</li>
<li>Level of consciousness (AVPU)</li>
</ul>

<h4>Total Score</h4>
<p>0‚Äì20</p>

<h4>Interpretation</h4>
<ul>
<li>0‚Äì4: Low risk</li>
<li>5‚Äì6: Medium risk ‚Üí urgent review</li>
<li>‚â•7: High risk ‚Üí critical care</li>
</ul>

<h4>Exam Pearl</h4>
<p>NEWS2 ‚â•5 requires urgent clinical escalation.</p>
`
}
,
{
name:"Braden Scale",
keywords:["braden","pressure ulcer","bedsore","nursing"],
html:`
<h4>Definition</h4>
<p>Predicts risk of pressure ulcer development.</p>

<h4>Components</h4>
<ul>
<li>Sensory perception</li>
<li>Moisture</li>
<li>Activity</li>
<li>Mobility</li>
<li>Nutrition</li>
<li>Friction & shear</li>
</ul>

<h4>Score Range</h4>
<p>6‚Äì23</p>

<h4>Interpretation</h4>
<ul>
<li>‚â§9: Very high risk</li>
<li>10‚Äì12: High risk</li>
<li>13‚Äì14: Moderate risk</li>
<li>15‚Äì18: Mild risk</li>
</ul>

<h4>Clinical Use</h4>
<p>Nursing care planning and preventive strategies.</p>

<h4>Limitations</h4>
<ul>
<li>Subjective scoring</li>
<li>Does not replace skin assessment</li>
</ul>
`
},

{
name:"Mini-Mental State Examination (MMSE)",
keywords:["mmse","mini mental","cognitive","dementia"],
html:`
<h4>Definition</h4>
<p>Screening tool for global cognitive function.</p>

<h4>Domains</h4>
<ul>
<li>Orientation</li>
<li>Registration</li>
<li>Attention & calculation</li>
<li>Recall</li>
<li>Language</li>
<li>Visuospatial ability</li>
</ul>

<h4>Score Range</h4>
<p>0‚Äì30</p>

<h4>Interpretation</h4>
<ul>
<li>‚â•24: Normal</li>
<li>18‚Äì23: Mild impairment</li>
<li>&lt;18: Severe impairment</li>
</ul>

<h4>Clinical Use</h4>
<p>Dementia screening and cognitive follow-up.</p>

<h4>Limitations</h4>
<ul>
<li>Affected by education and language</li>
<li>Poor sensitivity for mild cognitive impairment</li>
</ul>
`
},

{
name:"PHQ-9",
keywords:["phq9","depression","mental health","psychiatry"],
html:`
<h4>Definition</h4>
<p>Self-administered questionnaire assessing depression severity.</p>

<h4>Structure</h4>
<p>9 questions corresponding to DSM criteria for major depression.</p>

<h4>Score Range</h4>
<p>0‚Äì27</p>

<h4>Severity</h4>
<ul>
<li>0‚Äì4: Minimal</li>
<li>5‚Äì9: Mild</li>
<li>10‚Äì14: Moderate</li>
<li>15‚Äì19: Moderately severe</li>
<li>‚â•20: Severe</li>
</ul>

<h4>Clinical Use</h4>
<p>Primary care screening and treatment monitoring.</p>

<h4>Exam Pearl</h4>
<p>Question 9 screens for suicidal ideation.</p>
`
},

{
name:"GAD-7",
keywords:["gad7","anxiety","mental health","psychiatry"],
html:`
<h4>Definition</h4>
<p>Screening and severity tool for generalized anxiety disorder.</p>

<h4>Score Range</h4>
<p>0‚Äì21</p>

<h4>Interpretation</h4>
<ul>
<li>5: Mild</li>
<li>10: Moderate</li>
<li>15: Severe</li>
</ul>

<h4>Clinical Use</h4>
<p>Psychiatry and primary care screening.</p>

<h4>Limitations</h4>
<ul>
<li>Not diagnostic alone</li>
<li>Anxiety subtype overlap</li>
</ul>
`
},

{
name:"Beck Depression Inventory (BDI)",
keywords:["bdi","beck depression","depression scale"],
html:`
<h4>Definition</h4>
<p>Self-report inventory assessing depression severity.</p>

<h4>Structure</h4>
<p>21 items, each scored 0‚Äì3.</p>

<h4>Score Range</h4>
<p>0‚Äì63</p>

<h4>Interpretation</h4>
<ul>
<li>0‚Äì13: Minimal</li>
<li>14‚Äì19: Mild</li>
<li>20‚Äì28: Moderate</li>
<li>‚â•29: Severe</li>
</ul>

<h4>Clinical Use</h4>
<p>Psychiatry and research settings.</p>

<h4>Limitations</h4>
<p>Subjective with somatic symptom overlap.</p>
`
},

{
name:"Ottawa Ankle Rules",
keywords:["ottawa ankle","ankle xray","trauma"],
html:`
<h4>Definition</h4>
<p>Clinical decision rule to determine need for ankle or foot X-ray after trauma.</p>

<h4>Indications for X-ray</h4>
<ul>
<li>Bone tenderness at malleoli</li>
<li>Inability to bear weight (4 steps)</li>
<li>5th metatarsal base tenderness</li>
<li>Navicular tenderness</li>
</ul>

<h4>Clinical Impact</h4>
<ul>
<li>Reduces unnecessary imaging</li>
<li>High sensitivity (&gt;95%)</li>
</ul>

<h4>Limitation</h4>
<p>Low specificity.</p>
`
},

{
name:"Canadian CT Head Rule",
keywords:["canadian ct","head injury","ct scan","trauma"],
html:`
<h4>Definition</h4>
<p>Identifies patients with minor head injury requiring CT scan.</p>

<h4>High-Risk Criteria</h4>
<ul>
<li>GCS &lt;15 at 2 hours</li>
<li>Suspected open skull fracture</li>
<li>Basal skull fracture signs</li>
<li>‚â•2 vomiting episodes</li>
<li>Age ‚â•65</li>
</ul>

<h4>Medium Risk</h4>
<ul>
<li>Amnesia &gt;30 minutes</li>
<li>Dangerous mechanism</li>
</ul>

<h4>Exam Pearl</h4>
<p>Applies only if GCS 13‚Äì15.</p>
`
},

{
name:"Centor Score (Modified McIsaac)",
keywords:["centor","mcisaac","strep throat","pharyngitis"],
html:`
<h4>Definition</h4>
<p>Predicts probability of Group A streptococcal pharyngitis.</p>

<h4>Criteria</h4>
<ul>
<li>Tonsillar exudates</li>
<li>Tender anterior cervical nodes</li>
<li>Fever</li>
<li>Absence of cough</li>
<li>Age modifier</li>
</ul>

<h4>Score Range</h4>
<p>‚àí1 to +5</p>

<h4>Management</h4>
<ul>
<li>‚â§1: No testing</li>
<li>2‚Äì3: Rapid antigen test</li>
<li>‚â•4: Empiric antibiotics</li>
</ul>
`
},

{
name:"Duke Criteria (Infective Endocarditis)",
keywords:["duke","endocarditis","ie"],
html:`
<h4>Definition</h4>
<p>Diagnostic criteria for infective endocarditis.</p>

<h4>Major Criteria</h4>
<ul>
<li>Positive blood cultures (typical organisms)</li>
<li>Evidence of endocardial involvement (echo)</li>
</ul>

<h4>Minor Criteria</h4>
<ul>
<li>Predisposing condition</li>
<li>Fever</li>
<li>Vascular phenomena</li>
<li>Immunologic phenomena</li>
<li>Microbiologic evidence</li>
</ul>

<h4>Diagnosis</h4>
<ul>
<li>Definite: 2 major OR 1 major + 3 minor</li>
<li>Possible: 1 major + 1 minor</li>
</ul>
`
},

{
name:"Modified Rankin Scale (mRS)",
keywords:["mrs","rankin","stroke outcome"],
html:`
<h4>Definition</h4>
<p>Global disability scale used to assess functional outcome after stroke.</p>

<h4>Scale</h4>
<ul>
<li>0: No symptoms</li>
<li>1: No significant disability</li>
<li>2: Slight disability</li>
<li>3: Moderate disability</li>
<li>4: Moderately severe disability</li>
<li>5: Severe disability</li>
<li>6: Death</li>
</ul>

<h4>Clinical Use</h4>
<p>Stroke outcome measurement and rehabilitation planning.</p>

<h4>Exam Pearl</h4>
<p>mRS ‚â§2 indicates functional independence.</p>
`
},

{
name:"SIRS Criteria",
keywords:["sirs","sepsis","inflammatory response"],
html:`
<h4>Definition</h4>
<p>Defines systemic inflammatory response syndrome.</p>

<h4>Criteria (‚â•2)</h4>
<ul>
<li>Temperature &gt;38¬∞C or &lt;36¬∞C</li>
<li>Heart rate &gt;90 bpm</li>
<li>Respiratory rate &gt;20 or PaCO‚ÇÇ &lt;32 mmHg</li>
<li>WBC &gt;12,000 or &lt;4,000 or &gt;10% bands</li>
</ul>

<h4>Clinical Role</h4>
<p>Older sepsis screening tool.</p>

<h4>Limitations</h4>
<ul>
<li>Poor specificity</li>
<li>Replaced by SOFA/qSOFA in Sepsis-3</li>
</ul>

<h4>Exam Pearl</h4>
<p>SIRS ‚â† infection necessarily.</p>
`
}
,
{
name:"HScore (HLH)",
keywords:["hscore","hlh","hemophagocytic","ferritin","cytopenia"],
html:`
<h4>Definition</h4>
<p>Estimates probability of secondary hemophagocytic lymphohistiocytosis (HLH).</p>

<h4>Variables</h4>
<ul>
<li>Immunosuppression</li>
<li>Fever</li>
<li>Organomegaly</li>
<li>Cytopenias</li>
<li>Ferritin</li>
<li>Triglycerides</li>
<li>Fibrinogen</li>
<li>AST</li>
<li>Bone marrow hemophagocytosis</li>
</ul>

<h4>Score Range</h4>
<p>0‚Äì337</p>

<h4>Interpretation</h4>
<p>‚â•169 ‚Üí High probability of HLH.</p>

<h4>Clinical Use</h4>
<p>Hematology and ICU evaluation of unexplained fever and cytopenia.</p>

<h4>Limitations</h4>
<ul>
<li>Not validated in pediatrics</li>
<li>Bone marrow findings may be absent early</li>
</ul>
`
},

{
name:"CHA‚ÇÇDS‚ÇÇ-VASc-HS Score",
keywords:["cha2ds2","vasc-hs","stroke","afib"],
html:`
<h4>Definition</h4>
<p>Extended version of CHA‚ÇÇDS‚ÇÇ-VASc score to improve stroke risk prediction.</p>

<h4>Added Factors</h4>
<ul>
<li>Hyperlipidemia</li>
<li>Smoking</li>
</ul>

<h4>Clinical Status</h4>
<p>Research-based score, not yet guideline standard.</p>

<h4>Limitation</h4>
<p>Limited external validation.</p>
`
},

{
name:"PADUA Prediction Score",
keywords:["padua","vte","thrombosis","medical patients"],
html:`
<h4>Definition</h4>
<p>Assesses risk of venous thromboembolism in hospitalized medical patients.</p>

<h4>High-Risk Factors</h4>
<ul>
<li>Active cancer</li>
<li>Previous VTE</li>
<li>Reduced mobility</li>
<li>Thrombophilia</li>
<li>Trauma or surgery</li>
<li>Age ‚â•70</li>
</ul>

<h4>Interpretation</h4>
<p>Score ‚â•4 ‚Üí High VTE risk ‚Üí pharmacologic prophylaxis.</p>

<h4>Clinical Use</h4>
<p>Internal medicine wards and thromboprophylaxis decisions.</p>
`
},

{
name:"Caprini Score",
keywords:["caprini","vte","surgery","dvt risk"],
html:`
<h4>Definition</h4>
<p>Risk assessment model for venous thromboembolism in surgical patients.</p>

<h4>Factors</h4>
<ul>
<li>Age</li>
<li>BMI</li>
<li>Surgery type</li>
<li>Malignancy</li>
<li>Hormonal therapy</li>
<li>Previous VTE</li>
</ul>

<h4>Risk Categories</h4>
<ul>
<li>Low: 0‚Äì1</li>
<li>Moderate: 2</li>
<li>High: 3‚Äì4</li>
<li>Highest: ‚â•5</li>
</ul>

<h4>Clinical Use</h4>
<p>Pre-operative planning and guideline-recommended prophylaxis.</p>
`
},

{
name:"MUST Score",
keywords:["must","malnutrition","nutrition screening"],
html:`
<h4>Definition</h4>
<p>Malnutrition Universal Screening Tool for adults.</p>

<h4>Components</h4>
<ul>
<li>BMI</li>
<li>Unintentional weight loss</li>
<li>Acute illness effect</li>
</ul>

<h4>Score</h4>
<ul>
<li>0: Low risk</li>
<li>1: Medium risk</li>
<li>‚â•2: High risk</li>
</ul>

<h4>Clinical Use</h4>
<p>Hospital and community nutrition screening.</p>
`
},

{
name:"FIB-4 Index",
keywords:["fib4","liver fibrosis","nafld","hepatitis"],
html:`
<h4>Definition</h4>
<p>Non-invasive marker used to estimate liver fibrosis.</p>

<h4>Variables</h4>
<ul>
<li>Age</li>
<li>AST</li>
<li>ALT</li>
<li>Platelet count</li>
</ul>

<h4>Interpretation</h4>
<ul>
<li>&lt;1.3: Low fibrosis</li>
<li>‚â•2.67: Advanced fibrosis likely</li>
</ul>

<h4>Clinical Use</h4>
<p>Chronic hepatitis and NAFLD assessment.</p>

<h4>Advantage</h4>
<p>Avoids liver biopsy.</p>
`
},

{
name:"SAPS II",
keywords:["saps2","icu score","mortality"],
html:`
<h4>Definition</h4>
<p>Simplified Acute Physiology Score II predicting hospital mortality in ICU patients.</p>

<h4>Variables</h4>
<ul>
<li>Age</li>
<li>Vital signs</li>
<li>Laboratory values</li>
<li>Chronic disease</li>
<li>Admission type</li>
</ul>

<h4>Comparison</h4>
<ul>
<li>Less complex than APACHE II</li>
<li>Mainly used in research</li>
</ul>

<h4>Limitation</h4>
<p>Population-based, not for individual clinical decisions.</p>
`
},

{
name:"Shock Index",
keywords:["shock index","sepsis","trauma","hemodynamics"],
html:`
<h4>Definition</h4>
<p>Simple hemodynamic marker of early circulatory compromise.</p>

<h4>Formula</h4>
<p>Shock Index = Heart Rate / Systolic Blood Pressure</p>

<h4>Interpretation</h4>
<ul>
<li>0.5‚Äì0.7: Normal</li>
<li>‚â•1: Severe shock, high mortality</li>
</ul>

<h4>Clinical Use</h4>
<p>Trauma, sepsis, and emergency triage.</p>

<h4>Exam Pearl</h4>
<p>Shock index rises before hypotension appears.</p>
`
},

{
name:"Hunt‚ÄìHess Scale",
keywords:["hunt hess","sah","subarachnoid hemorrhage"],
html:`
<h4>Definition</h4>
<p>Clinical grading system assessing severity of subarachnoid hemorrhage.</p>

<h4>Scale</h4>
<ul>
<li>I: Asymptomatic or mild headache</li>
<li>II: Moderate headache, nuchal rigidity</li>
<li>III: Drowsiness, confusion</li>
<li>IV: Stupor, severe deficit</li>
<li>V: Coma</li>
</ul>

<h4>Clinical Use</h4>
<p>Prognosis estimation, surgical timing, ICU triage.</p>

<h4>Exam Pearl</h4>
<p>Higher grade correlates with higher mortality and vasospasm risk.</p>
`
},

{
name:"Fisher Scale",
keywords:["fisher scale","sah ct","vasospasm"],
html:`
<h4>Definition</h4>
<p>CT-based grading system predicting vasospasm risk after SAH.</p>

<h4>Scale</h4>
<ul>
<li>I: No blood</li>
<li>II: Thin diffuse blood</li>
<li>III: Thick clot (&gt;1 mm)</li>
<li>IV: Intraventricular or intracerebral hemorrhage</li>
</ul>

<h4>Clinical Use</h4>
<p>Vasospasm risk stratification and ICU monitoring.</p>

<h4>Limitation</h4>
<p>Does not assess clinical status.</p>
`
},

{
name:"Wells‚ÄìRiley Score",
keywords:["wells riley","tb transmission","tuberculosis"],
html:`
<h4>Definition</h4>
<p>Epidemiological model estimating airborne tuberculosis transmission risk.</p>

<h4>Formula Includes</h4>
<ul>
<li>Number of infectious individuals</li>
<li>Ventilation rate</li>
<li>Exposure time</li>
<li>Infectious quanta</li>
</ul>

<h4>Clinical Use</h4>
<p>Public health, infection control, hospital isolation planning.</p>

<h4>Limitation</h4>
<ul>
<li>Assumption-based</li>
<li>Not used for individual diagnosis</li>
</ul>
`
}
,
{
name:"Maddrey‚Äôs Discriminant Function (DF)",
keywords:["maddrey","df","alcoholic hepatitis","steroids"],
html:`
<h4>Definition</h4>
<p>Predicts mortality in alcoholic hepatitis and guides corticosteroid therapy.</p>

<h4>Formula</h4>
<p>DF = 4.6 √ó (PT prolongation) + serum bilirubin (mg/dL)</p>

<h4>Interpretation</h4>
<ul>
<li>DF ‚â•32: Severe disease ‚Üí consider corticosteroids</li>
</ul>

<h4>Clinical Use</h4>
<p>Hepatology management and ICU admission decisions.</p>

<h4>Limitations</h4>
<ul>
<li>PT variability</li>
<li>Less accurate than MELD in some studies</li>
</ul>

<h4>Exam Pearl</h4>
<p>DF ‚â•32 = high short-term mortality.</p>
`
},

{
name:"Lille Score",
keywords:["lille score","alcoholic hepatitis","steroid response"],
html:`
<h4>Definition</h4>
<p>Evaluates response to corticosteroids in severe alcoholic hepatitis.</p>

<h4>Variables</h4>
<ul>
<li>Age</li>
<li>Albumin</li>
<li>Bilirubin (day 0 and day 7)</li>
<li>Creatinine</li>
<li>Prothrombin time</li>
</ul>

<h4>Interpretation</h4>
<p>Score >0.45 ‚Üí Non-responder ‚Üí stop steroids.</p>

<h4>Clinical Use</h4>
<p>Prevents unnecessary steroid exposure.</p>

<h4>Advantage</h4>
<p>Dynamic, response-based score.</p>
`
},

{
name:"CRB-65 Score",
keywords:["crb-65","pneumonia","severity","primary care"],
html:`
<h4>Definition</h4>
<p>Simplified pneumonia severity score excluding urea measurement.</p>

<h4>Components</h4>
<ul>
<li>Confusion</li>
<li>Respiratory rate ‚â•30</li>
<li>Blood pressure <90/60</li>
<li>Age ‚â•65</li>
</ul>

<h4>Interpretation</h4>
<p>Score ‚â•2 ‚Üí hospital admission.</p>

<h4>Clinical Use</h4>
<p>Primary care and resource-limited settings.</p>
`
},

{
name:"Child‚ÄìTurcotte Score",
keywords:["child turcotte","liver disease","cirrhosis"],
html:`
<h4>Definition</h4>
<p>Original scoring system for liver disease severity before INR inclusion.</p>

<h4>Components</h4>
<ul>
<li>Ascites</li>
<li>Encephalopathy</li>
<li>Nutritional status</li>
<li>Albumin</li>
<li>Bilirubin</li>
</ul>

<h4>Historical Importance</h4>
<p>Basis for the modern Child‚ÄìPugh score.</p>

<h4>Limitations</h4>
<ul>
<li>Subjective nutritional assessment</li>
<li>Largely obsolete</li>
</ul>
`
},

{
name:"McCabe Score",
keywords:["mccabe","prognosis","sepsis"],
html:`
<h4>Definition</h4>
<p>Classifies severity of underlying disease based on life expectancy.</p>

<h4>Categories</h4>
<ul>
<li>Non-fatal disease</li>
<li>Ultimately fatal disease (‚â§5 years)</li>
<li>Rapidly fatal disease (‚â§1 year)</li>
</ul>

<h4>Clinical Use</h4>
<p>Infection prognosis studies and sepsis research.</p>

<h4>Limitation</h4>
<p>Broad categories; rarely used clinically today.</p>
`
},

{
name:"pSOFA Score",
keywords:["psofa","pediatric sepsis","organ failure"],
html:`
<h4>Definition</h4>
<p>Pediatric adaptation of SOFA score for organ dysfunction.</p>

<h4>Systems Assessed</h4>
<ul>
<li>Respiratory</li>
<li>Cardiovascular</li>
<li>Hepatic</li>
<li>Coagulation</li>
<li>Renal</li>
<li>Neurologic (age-adjusted GCS)</li>
</ul>

<h4>Clinical Use</h4>
<p>Pediatric sepsis diagnosis and ICU prognosis.</p>

<h4>Advantage</h4>
<p>Age-adjusted variables.</p>
`
},

{
name:"LACE Index",
keywords:["lace index","readmission","discharge planning"],
html:`
<h4>Definition</h4>
<p>Predicts 30-day readmission or death after hospital discharge.</p>

<h4>Components</h4>
<ul>
<li>Length of stay</li>
<li>Acuity of admission</li>
<li>Comorbidities (Charlson Index)</li>
<li>Emergency visits (past 6 months)</li>
</ul>

<h4>Score Range</h4>
<p>0‚Äì19</p>

<h4>Interpretation</h4>
<p>Score ‚â•10 ‚Üí high readmission risk.</p>

<h4>Clinical Use</h4>
<p>Discharge planning and transitional care programs.</p>
`
},

{
name:"CHADS‚ÇÇ Score",
keywords:["chads2","afib","stroke risk"],
html:`
<h4>Definition</h4>
<p>Early clinical prediction rule estimating annual stroke risk in atrial fibrillation.</p>

<h4>Components</h4>
<ul>
<li>Congestive heart failure</li>
<li>Hypertension</li>
<li>Age ‚â•75</li>
<li>Diabetes mellitus</li>
<li>Stroke/TIA (2 points)</li>
</ul>

<h4>Score Range</h4>
<p>0‚Äì6</p>

<h4>Limitations</h4>
<ul>
<li>Underestimates risk in low-risk patients</li>
<li>Does not include vascular disease or age 65‚Äì74</li>
</ul>

<h4>Exam Pearl</h4>
<p>Foundation for CHA‚ÇÇDS‚ÇÇ-VASc.</p>
`
},

{
name:"AIMS65 Score",
keywords:["aims65","ugi bleeding","icu risk"],
html:`
<h4>Definition</h4>
<p>Predicts in-hospital mortality in upper gastrointestinal bleeding.</p>

<h4>Components</h4>
<ul>
<li>Albumin <3.0 g/dL</li>
<li>INR >1.5</li>
<li>Altered mental status</li>
<li>Systolic BP ‚â§90 mmHg</li>
<li>Age ‚â•65</li>
</ul>

<h4>Score Range</h4>
<p>0‚Äì5</p>

<h4>Interpretation</h4>
<ul>
<li>‚â•2: Increased mortality risk</li>
<li>‚â•3: ICU consideration</li>
</ul>

<h4>Limitation</h4>
<p>Does not predict rebleeding well.</p>
`
},

{
name:"CALL Score (COVID-19)",
keywords:["call score","covid","pneumonia severity"],
html:`
<h4>Definition</h4>
<p>Predicts progression to severe COVID-19 pneumonia.</p>

<h4>Components</h4>
<ul>
<li>Comorbidity</li>
<li>Age</li>
<li>Lymphocyte count</li>
<li>LDH level</li>
</ul>

<h4>Interpretation</h4>
<p>Higher score ‚Üí higher risk of respiratory deterioration.</p>

<h4>Clinical Use</h4>
<p>COVID ward triage and resource allocation.</p>

<h4>Limitation</h4>
<p>Disease-specific and less relevant post-pandemic.</p>
`
},

{
name:"CURB Score (Without Age)",
keywords:["curb","pneumonia","severity"],
html:`
<h4>Definition</h4>
<p>Simplified pneumonia severity score derived from CURB-65 excluding age.</p>

<h4>Components</h4>
<ul>
<li>Confusion</li>
<li>Urea >7 mmol/L</li>
<li>Respiratory rate ‚â•30</li>
<li>Blood pressure <90/60</li>
</ul>

<h4>Clinical Use</h4>
<p>Younger patients or situations where age skews severity.</p>

<h4>Limitation</h4>
<p>Less validated than CURB-65.</p>
`
}
,
{
name:"CHA‚ÇÇDS‚ÇÇ-VASc-R Score",
keywords:["cha2ds2-vasc-r","afib","renal","ckd","stroke risk"],
html:`
<h4>Definition</h4>
<p>Modified stroke risk score including renal dysfunction.</p>

<h4>Added Variable</h4>
<p>Renal impairment (eGFR &lt;60 mL/min).</p>

<h4>Purpose</h4>
<p>Improves stroke risk prediction in CKD patients with atrial fibrillation.</p>

<h4>Status</h4>
<ul>
<li>Research-based</li>
<li>Not guideline standard</li>
</ul>
`
},

{
name:"QUICKI Index",
keywords:["quicki","insulin sensitivity","diabetes","endocrinology"],
html:`
<h4>Definition</h4>
<p>Quantitative Insulin Sensitivity Check Index estimating insulin sensitivity.</p>

<h4>Formula</h4>
<p>1 / [log(fasting insulin) + log(fasting glucose)]</p>

<h4>Interpretation</h4>
<p>Lower QUICKI values indicate insulin resistance.</p>

<h4>Clinical Use</h4>
<p>Endocrinology and metabolic syndrome research.</p>

<h4>Limitation</h4>
<p>Requires fasting insulin, not routinely measured.</p>
`
},

{
name:"NAFLD Fibrosis Score (NFS)",
keywords:["nafld","fibrosis","nfs","liver"],
html:`
<h4>Definition</h4>
<p>Non-invasive score predicting advanced fibrosis in NAFLD.</p>

<h4>Variables</h4>
<ul>
<li>Age</li>
<li>BMI</li>
<li>Diabetes</li>
<li>AST/ALT ratio</li>
<li>Platelet count</li>
<li>Albumin</li>
</ul>

<h4>Interpretation</h4>
<ul>
<li>Low score ‚Üí excludes advanced fibrosis</li>
<li>High score ‚Üí advanced fibrosis likely</li>
</ul>

<h4>Advantage</h4>
<p>Reduces need for liver biopsy.</p>
`
},

{
name:"BODE Index",
keywords:["bode","copd","prognosis","pulmonology"],
html:`
<h4>Definition</h4>
<p>Predicts mortality in chronic obstructive pulmonary disease (COPD).</p>

<h4>Components</h4>
<ul>
<li>BMI</li>
<li>Airflow obstruction (FEV‚ÇÅ)</li>
<li>Dyspnea (mMRC scale)</li>
<li>Exercise capacity (6-minute walk)</li>
</ul>

<h4>Score Range</h4>
<p>0‚Äì10</p>

<h4>Interpretation</h4>
<p>Higher score indicates worse prognosis.</p>

<h4>Exam Pearl</h4>
<p>BODE index is more prognostic than FEV‚ÇÅ alone.</p>
`
},

{
name:"MELD-XI Score",
keywords:["meld-xi","liver","heart failure","anticoagulation"],
html:`
<h4>Definition</h4>
<p>Modified MELD score excluding INR when INR is unreliable.</p>

<h4>Variables</h4>
<ul>
<li>Serum creatinine</li>
<li>Serum bilirubin</li>
</ul>

<h4>Clinical Use</h4>
<p>Patients on anticoagulation or advanced heart failure.</p>

<h4>Limitation</h4>
<p>Less accurate than MELD-Na.</p>
`
},

{
name:"FOUR Score",
keywords:["four score","coma","icu","neurology"],
html:`
<h4>Definition</h4>
<p>Full Outline of UnResponsiveness neurological coma scale.</p>

<h4>Components</h4>
<ul>
<li>Eye response</li>
<li>Motor response</li>
<li>Brainstem reflexes</li>
<li>Respiration pattern</li>
</ul>

<h4>Score Range</h4>
<p>0‚Äì16</p>

<h4>Advantages</h4>
<ul>
<li>No verbal component</li>
<li>Better ICU prognostic value</li>
</ul>

<h4>Exam Pearl</h4>
<p>Superior to GCS in intubated patients.</p>
`
},

{
name:"Charlson Comorbidity Index (CCI)",
keywords:["charlson","comorbidity","mortality","lace"],
html:`
<h4>Definition</h4>
<p>Weighted index predicting 10-year mortality based on comorbid conditions.</p>

<h4>Components</h4>
<p>19 conditions with weights from 1‚Äì6 (e.g. CHF, CKD, malignancy, AIDS).</p>

<h4>Scoring</h4>
<p>Higher total score indicates higher mortality risk.</p>

<h4>Clinical Use</h4>
<ul>
<li>Prognostic stratification</li>
<li>Research adjustment</li>
<li>Used within LACE index</li>
</ul>

<h4>Exam Pearl</h4>
<p>CCI is prognostic, not a treatment guide.</p>
`
},

{
name:"Killip‚ÄìKimball Classification",
keywords:["killip","acs","heart failure","mi"],
html:`
<h4>Definition</h4>
<p>Clinical classification of heart failure severity in acute myocardial infarction.</p>

<h4>Classes</h4>
<ul>
<li>I: No heart failure</li>
<li>II: S3 gallop, basal crackles</li>
<li>III: Acute pulmonary edema</li>
<li>IV: Cardiogenic shock</li>
</ul>

<h4>Prognostic Value</h4>
<p>Higher class indicates higher in-hospital mortality.</p>

<h4>Exam Pearl</h4>
<p>Killip IV = highest mortality.</p>
`
},

{
name:"Blatchford‚ÄìRockall Combined Score",
keywords:["blatchford","rockall","ugi bleeding"],
html:`
<h4>Definition</h4>
<p>Combines Glasgow-Blatchford Score (triage) with Rockall Score (mortality).</p>

<h4>Clinical Logic</h4>
<ul>
<li>GBS ‚Üí need for intervention</li>
<li>Rockall ‚Üí mortality and rebleeding risk</li>
</ul>

<h4>Clinical Use</h4>
<p>Upper GI bleeding pathways and audits.</p>

<h4>Limitation</h4>
<p>Requires endoscopy for full application.</p>
`
},

{
name:"MELD-Na Score",
keywords:["meld-na","liver transplant","cirrhosis"],
html:`
<h4>Definition</h4>
<p>Updated MELD score including serum sodium.</p>

<h4>Variables</h4>
<ul>
<li>Bilirubin</li>
<li>INR</li>
<li>Creatinine</li>
<li>Sodium</li>
</ul>

<h4>Clinical Importance</h4>
<p>Current standard for liver transplant allocation.</p>

<h4>Exam Pearl</h4>
<p>MELD-Na replaced MELD in most transplant systems.</p>
`
},

{
name:"De Ritis Ratio (AST/ALT)",
keywords:["de ritis","ast alt","liver disease"],
html:`
<h4>Definition</h4>
<p>Biochemical ratio used to assess liver disease etiology and severity.</p>

<h4>Interpretation</h4>
<ul>
<li>&lt;1: Viral hepatitis</li>
<li>‚âà2: Alcoholic liver disease</li>
<li>‚âà1: Advanced fibrosis or cirrhosis</li>
</ul>

<h4>Clinical Use</h4>
<p>Hepatology and prognostic assessment.</p>

<h4>Limitation</h4>
<p>Affected by muscle injury and hemolysis.</p>
`
}
,
{
name:"CURS Score (Cardiac Surgery Risk Score)",
keywords:["curs","cardiac surgery","perioperative mortality"],
html:`
<h4>Definition</h4>
<p>Simplified risk score predicting perioperative mortality in cardiac surgery.</p>

<h4>Variables</h4>
<ul>
<li>Age</li>
<li>Left ventricular function</li>
<li>Renal dysfunction</li>
<li>Urgency of surgery</li>
</ul>

<h4>Clinical Use</h4>
<ul>
<li>Preoperative counseling</li>
<li>Surgical risk stratification</li>
</ul>

<h4>Limitation</h4>
<p>Superseded by EuroSCORE II in many centers.</p>
`
},

{
name:"EuroSCORE II",
keywords:["euroscore ii","cardiac surgery","operative mortality"],
html:`
<h4>Definition</h4>
<p>Predicts operative mortality in cardiac surgery patients.</p>

<h4>Variables</h4>
<ul>
<li>Patient factors (age, renal function)</li>
<li>Cardiac status</li>
<li>Operation complexity</li>
</ul>

<h4>Output</h4>
<p>Predicted mortality percentage.</p>

<h4>Clinical Use</h4>
<ul>
<li>Cardiac surgery planning</li>
<li>Benchmarking surgical outcomes</li>
</ul>

<h4>Exam Pearl</h4>
<p>EuroSCORE II is more accurate than the original EuroSCORE.</p>
`
},

{
name:"STOP-BANG Questionnaire",
keywords:["stop-bang","sleep apnea","osa","anesthesia"],
html:`
<h4>Definition</h4>
<p>Screening questionnaire for obstructive sleep apnea (OSA).</p>

<h4>Components</h4>
<ul>
<li>Snoring</li>
<li>Tiredness</li>
<li>Observed apnea</li>
<li>Pressure (hypertension)</li>
<li>BMI &gt;35</li>
<li>Age &gt;50</li>
<li>Neck circumference</li>
<li>Male gender</li>
</ul>

<h4>Interpretation</h4>
<p>Score ‚â•3 indicates high risk of OSA.</p>

<h4>Clinical Use</h4>
<ul>
<li>Preoperative assessment</li>
<li>Sleep clinic screening</li>
</ul>

<h4>Limitation</h4>
<p>High sensitivity but low specificity.</p>
`
},

{
name:"SOAR Score",
keywords:["soar","stroke prognosis","ischemic stroke"],
html:`
<h4>Definition</h4>
<p>Predicts mortality after acute ischemic stroke.</p>

<h4>Components</h4>
<ul>
<li>Stroke subtype</li>
<li>Oxfordshire classification</li>
<li>Age</li>
<li>Pre-stroke disability</li>
</ul>

<h4>Clinical Use</h4>
<ul>
<li>Early prognostic counseling</li>
<li>Research stratification</li>
</ul>

<h4>Limitation</h4>
<p>Less commonly used than NIHSS combined with mRS.</p>
`
},

{
name:"CURB-RS Score",
keywords:["curb-rs","pneumonia","renal dysfunction"],
html:`
<h4>Definition</h4>
<p>Renal-sensitive pneumonia severity score.</p>

<h4>Components</h4>
<ul>
<li>CURB-65 variables</li>
<li>Renal impairment (eGFR &lt;60 mL/min)</li>
</ul>

<h4>Purpose</h4>
<p>Improves mortality prediction in elderly and CKD patients.</p>

<h4>Status</h4>
<ul>
<li>Research-based</li>
<li>Limited clinical adoption</li>
</ul>
`
}
];
/* =====================
   CORE LOGIC
===================== */
const list = document.getElementById("list");
const search = document.getElementById("search");
const modal = document.getElementById("modal");
const content = document.getElementById("content");
const suggestions = document.getElementById("suggestions");

const normalize = s => s.toLowerCase().replace(/[^a-z0-9]/g,"");

function openModal(s){
  content.innerHTML=`<h2>${s.name}</h2>`+s.html;
  modal.style.display="flex";
}

function closeModal(){ modal.style.display="none"; }

search.addEventListener("input",e=>{
  const q = normalize(e.target.value);
  suggestions.innerHTML="";
  if(!q){ suggestions.style.display="none"; return; }

  const matches = scores.filter(s =>
    normalize(s.name).includes(q) ||
    normalize(s.keywords.join(" ")).includes(q)
  );

  if(!matches.length){ suggestions.style.display="none"; return; }

  suggestions.style.display="block";
  matches.forEach(s=>{
    const d=document.createElement("div");
    d.className="suggestion";
    d.textContent=s.name;
    d.onclick=()=>{ openModal(s); suggestions.style.display="none"; };
    suggestions.appendChild(d);
  });
});
</script>

</body>
</html>
